UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHED	\mathbf{H}	13C
SCHED	ULL	1JU

Under the Securities Exchange Act of 1934 (Amendment No.)*

Oculis Holding AG

(Name of Issuer)

Ordinary Shares, CHF 0.01 par value per share (Title of Class of Securities)

H5870P102 (CUSIP Number)

December 3, 2024 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1	NAMES O	F RE	EPORTING PERSONS	
			p Holdings Limited	
2		ΗΕ <i>Α</i> (b) ∃	APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	
	(a) 🗆	(D)		
3	SEC USE C	DNL	Y	
4	CITIZENSI	HIP	OR PLACE OF ORGANIZATION	
	British Virg			
		5	SOLE VOTING POWER	
			0	
	UMBER OF SHARES	6	SHARED VOTING POWER	
	SHAKES NEFICIALLY			
	WNED BY		2,174,074	
	EACH	7	SOLE DISPOSITIVE POWER	
	EPORTING PERSON			
	WITH:	8	SHARED DISPOSITIVE POWER	
			OIL MED DIG CONTYL TO WER	
			2,174,074	
9	AGGREGA	TE.	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	2 174 074			
10	2,174,074)V I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	
10	CHECK BO	<i>J</i>	THE AGGREGATE AMOUNT IN ROW (3) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	
11	PERCENT	OF	CLASS REPRESENTED BY AMOUNT IN ROW 9	
12	5.2%) FD4	ORTING BERGON (SEE INSTRUCTIONS)	
12	TYPEOFF	(EP	ORTING PERSON (SEE INSTRUCTIONS)	
	CO			

1	NAMES OF	FRE	EPORTING PERSONS	
	NF Investment Holdings Limited			
2	CHECK TH	IE A	PPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)	
	(a) \Box	(b) l		
3	SEC USE C	NL	Y	
	CATALON 101	***		
4	CITIZENSI	HIP	OR PLACE OF ORGANIZATION	
	British Virg	in Is	slands	
		5	SOLE VOTING POWER	
			0	
	UMBER OF SHARES	6	SHARED VOTING POWER	
BEN	NEFICIALLY		2,174,074	
O	WNED BY EACH	7	SOLE DISPOSITIVE POWER	
	EPORTING			
	PERSON WITH:	8	0 SHARED DISPOSITIVE POWER	
	WIIII.	o	SHARED DISTOSITIVE FOWER	
			2,174,074	
9	AGGREGA	TE.	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	2,174,074			
10	CHECK BO)X I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	
11	PERCENT	OF	CLASS REPRESENTED BY AMOUNT IN ROW 9	
	5.2%			
12		REPO	ORTING PERSON (SEE INSTRUCTIONS)	
	G0			
	CO			

1	NAMES OF REPORTING PERSONS		
	Nan Fung Life Sciences Holdings Limited		
2		HE A	APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) ☑
3	SEC USE C	NL	Y
4	CITIZENSI	HIP	OR PLACE OF ORGANIZATION
	British Virg	in Is	slands
		5	SOLE VOTING POWER
NII	IMPER OF		0
	JMBER OF SHARES	6	SHARED VOTING POWER
	NEFICIALLY WNED BY		2,174,074
	EACH	7	SOLE DISPOSITIVE POWER
	EPORTING PERSON		0
	WITH:	8	SHARED DISPOSITIVE POWER
			2,174,074
9	AGGREGA	TE.	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	2,174,074		
10	CHECK BO)X I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
11	PERCENT	OF	CLASS REPRESENTED BY AMOUNT IN ROW 9
	5.2%		
12	TYPE OF R	REPO	ORTING PERSON (SEE INSTRUCTIONS)
	CO		

1	NAMESO	EDI	EPORTING PERSONS		
1	IVAIVILS OF KLI OKTING FERSONS				
	NFLS Platform Holdings Limited				
2			APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)		
		1E F (b)			
	(a) 🗆	(0)			
3	SEC USE ()NI	V		
3	SEC OSE ()1 11	1		
4	CITIZENS	HIP	OR PLACE OF ORGANIZATION		
	CITIZENS	1111	OKTENCE OF OKOMINEMION		
	Cayman Isl	ands			
		5	SOLE VOTING POWER		
	UMBER OF	6	SHARED VOTING POWER		
	SHARES NEFICIALLY				
	WNED BY		436,378		
	EACH	7	SOLE DISPOSITIVE POWER		
R	EPORTING				
	PERSON		0		
	WITH:	8	SHARED DISPOSITIVE POWER		
			436,378		
9	AGGREGA	TE.	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	436,378				
10	CHECK BO	OX I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
11	PERCENT	OF	CLASS REPRESENTED BY AMOUNT IN ROW 9		
	1.0%				
12	TYPE OF F	(EP	ORTING PERSON (SEE INSTRUCTIONS)		
	00				
	CO				
ļ!					

1	NAMES OF REPORTING PERSONS		
	NFLS Beta Limited		
2	2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) □ (b) ⊠		
3	SEC USE ONLY		
4	CITIZENSI	HIP	OR PLACE OF ORGANIZATION
	British Virg	in Is	
		5	SOLE VOTING POWER
NII	IMPER OF		0
	JMBER OF SHARES	6	SHARED VOTING POWER
	NEFICIALLY WNED BY		436,378
	EACH	7	SOLE DISPOSITIVE POWER
	EPORTING PERSON		0
	WITH:	8	SHARED DISPOSITIVE POWER
			427.270
9	AGGREGA	TE	436,378 AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	110011201		
	436,378		
10	CHECK BO)X I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
11	PERCENT	OF	CLASS REPRESENTED BY AMOUNT IN ROW 9
	1.0%		
12		REP	ORTING PERSON (SEE INSTRUCTIONS)
	CO		
L			

1	NAMES O	FRE	EPORTING PERSONS
	Pivotal Life Sciences Holdings Limited		
2		HE A	APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) ☑
3	SEC USE C	DNL	Y
4	CITIZENSI	HIP	OR PLACE OF ORGANIZATION
	Cayman Isl	ands	
		5	SOLE VOTING POWER
NII	IMPER OF		0
	JMBER OF SHARES	6	SHARED VOTING POWER
	NEFICIALLY WNED BY		1,737,696
	EACH	7	SOLE DISPOSITIVE POWER
	EPORTING PERSON		0
	WITH:	8	SHARED DISPOSITIVE POWER
			1,737,696
9	AGGREGA	TE.	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	1,737,696		
10	CHECK BO)X I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
11	PERCENT	OF	CLASS REPRESENTED BY AMOUNT IN ROW 9
	4.2%		
12	TYPE OF F	REPO	ORTING PERSON (SEE INSTRUCTIONS)
	СО		
ь——			

1	NAMES O	F RI	EPORTING PERSONS		
	Pivotal Partners Ltd				
2		ΗΕ <i>Α</i> (b) □	APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) ▼		
	(a) 🗆 ((0)			
3	SEC USE C	ONL	Y		
4	CITIZENSI	НІР	OR PLACE OF ORGANIZATION		
7	CITIZENSI	1111	ORTEACE OF ORGANIZATION		
	Cayman Isl				
		5	SOLE VOTING POWER		
	UMBER OF SHARES	6	SHARED VOTING POWER		
	NEFICIALLY		1.727.606		
О	WNED BY EACH	7	1,737,696 SOLE DISPOSITIVE POWER		
R	EACH EPORTING	′	SOLD DISTORTIVE TO WERE		
	PERSON		0		
	WITH:	8	SHARED DISPOSITIVE POWER		
			1,737,696		
9	AGGREGA	TE.	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,737,696				
10		OX I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
	_				
11	DEDCENIT	OF	CLASS REPRESENTED BY AMOUNT IN ROW 9		
11	FERCENT	OΓ	CLASS REI RESENTED DI AMOUNT IN ROW 7		
	4.2%				
12	TYPE OF F	REP	ORTING PERSON (SEE INSTRUCTIONS)		
	CO				
ļ!					

1	NAMES OF	FRE	EPORTING PERSONS	
	Pivotal bioVenture Partners Fund I U.G.P. Ltd.			
2		HE A	APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) ☑	
3	SEC USE C	NL	Y	
4	CITIZENSI	HIP	OR PLACE OF ORGANIZATION	
	Cayman Isla	ands		
		5	SOLE VOTING POWER	
NII	IMPER OF		0	
	JMBER OF SHARES	6	SHARED VOTING POWER	
	NEFICIALLY WNED BY		1,737,696	
	EACH	7	SOLE DISPOSITIVE POWER	
	EPORTING PERSON		0	
	WITH:	8	SHARED DISPOSITIVE POWER	
			1,737,696	
9	AGGREGA	TE.	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1,737,696			
10	CHECK BO)X I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	
11	PERCENT	OF	CLASS REPRESENTED BY AMOUNT IN ROW 9	
	4.2%			
12		REPO	ORTING PERSON (SEE INSTRUCTIONS)	
	CO			
Ļ——!				

1	NAMES OF REPORTING PERSONS			
	Pivotal bioVenture Partners Fund I G.P., L.P.			
2		HE A	APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) ☑	
3	SEC USE C	NL	Y	
4	CITIZENSI	HIP	OR PLACE OF ORGANIZATION	
	Cayman Isla	ands		
		5	SOLE VOTING POWER	
NII	JMBER OF		0	
	SHARES	6	SHARED VOTING POWER	
	NEFICIALLY WNED BY		1,737,696	
	EACH	7	SOLE DISPOSITIVE POWER	
	EPORTING PERSON		0	
	WITH:	8	SHARED DISPOSITIVE POWER	
			1,737,696	
9	AGGREGA	TE.	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1,737,696			
10	CHECK BO)X I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	
11	PERCENT	OF	CLASS REPRESENTED BY AMOUNT IN ROW 9	
	4.2%			
12	TYPE OF R	REPO	ORTING PERSON (SEE INSTRUCTIONS)	
	PN			
ь——				

			
1	NAMES OF REPORTING PERSONS		
	Pivotal bioVenture Partners Fund I, L.P.		
2			APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
	(a) \Box ((b) l	<u>N</u>
3	SEC USE C	NL	Y
4	CITIZENSI	HIP	OR PLACE OF ORGANIZATION
	Cayman Isla	ands	
	,	5	SOLE VOTING POWER
NI	JMBER OF		0
	SHARES	6	SHARED VOTING POWER
BEN	NEFICIALLY		1.505.606
O.	WNED BY	-	1,737,696
D.	EACH	7	SOLE DISPOSITIVE POWER
	EPORTING PERSON		0
	WITH:	8	SHARED DISPOSITIVE POWER
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Ü	SIMILES BISTOSTIVETOWER
			1,737,696
9	AGGREGA	TE.	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
10	1,737,696		
10	CHECK BO)X I	F THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
11		OF	CLASS REPRESENTED BY AMOUNT IN ROW 9
	4.2%		
12	TYPE OF R	REPO	ORTING PERSON (SEE INSTRUCTIONS)
	D. 1		
	PN		

Item 1(a). Name of Issuer:

Oculis Holding AG (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

Bahnhofstrasse 7 CH-6300 Zug, Switzerland

Item 2(a). Names of Persons Filing:

The names of the persons filing this report (collectively, the "Reporting Persons") are:

- (i) Nan Fung Group Holdings Limited ("NFGHL")
- (ii) NF Investment Holdings Limited ("NFIHL")
- (iii) Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences")
- (iv) NFLS Platform Holdings Limited ("NFLS Platform")
- (v) NFLS Beta Limited ("NFLS Beta")
- (vi) Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences")
- (vii) Pivotal Partners Ltd ("Pivotal Partners")
- (viii) Pivotal bioVenture Partners Fund I U.G.P. Ltd (the "Ultimate General Partner")
- (ix) Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP")
- (x) Pivotal bioVenture Partners Fund I, L.P. ("Pivotal," and together with Pivotal Life Sciences, Pivotal Partners, Ultimate General Partner, and Pivotal GP, the "Pivotal Entities")

Item 2(b). Address of Principal Business Office or, if None, Residence:

The address of the principal business office of each of the Pivotal Entities is 501 Second Street, Suite 200, San Francisco, CA 94107. The principal business address of NFGHL is 17th Floor, AIRSIDE, 2 Concorde Road, Kai Tak, Hong Kong. The registered office address of each of NFIHL, Nan Fung Life Sciences and NFLS Beta is Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands.

Item 2(c). <u>Citizenship</u>:

Pivotal is a Cayman Islands exempted limited partnership. Pivotal GP is a Cayman Islands exempted limited partnership. Ultimate General Partner is a Cayman Islands exempted company. Pivotal Life Sciences is a Cayman Islands exempted company. Pivotal Life Sciences is a Cayman Islands exempted company. Nan Fung Life Sciences, NFIHL and NFGHL are incorporated in the British Virgin Islands. NFLS Beta is incorporated in the British Virgin Islands and NFLS Platform is incorporated in the Cayman Islands. Mr. Kam Chung Leung, Mr. Pui Kuen Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are citizens of the Hong Kong Special Administrative Region of the People's Republic of China. Ms. Heqing Huang is a citizen of the People's Republic of China. Mr. Frank Kai Shui Seto is a citizen of Canada. Mr. Vincent Sai Sing Cheung and Ms. Vanessa Tih Lin Cheung are citizens of the United Kingdom.

Item 2(d). <u>Title of Class of Securities</u>:

Ordinary Shares, CHF 0.01 par value per share ("Ordinary Shares")

Item 2(e). CUSIP Number:

H5870P102

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4. Ownership.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages are based on 41,745,295 outstanding Ordinary Shares as reported in the Issuer's Prospectus filed pursuant to Rule 424(b)(3) filed on September 6, 2024.

Pivotal directly holds 1,737,696 Ordinary Shares. NFLS Beta directly holds 436,378 Ordinary Shares. Pivotal GP is the general partner of Pivotal, and Ultimate General Partner is the general partner of Pivotal GP. Ultimate General Partner is wholly-owned by Pivotal Partners. Pivotal Partners is wholly-owned by Pivotal Life Sciences. Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences, and Nan Fung Life Sciences is wholly-owned by NFIHL, which is wholly owned by NFGHL. NFLS Beta is wholly-owned by NFLS Platform, which is wholly-owned by Nan Fung Life Sciences. The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal and NFLS Beta. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Heqing Huang and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following \Box .

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. <u>Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.</u>

Not applicable.

Item 8. <u>Identification and Classification of Members of the Group.</u>

Not applicable.

Item 9. <u>Notice of Dissolution of Group.</u>

Not applicable.

Item 10. <u>Certification</u>.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Date: December 9, 2024

NAN FUNG GROUP HOLDINGS LIMITED

By: /s/ Tang Chun Wai Nelson

Name: Tang Chun Wai Nelson

Title: Director

NF INVESTMENT HOLDINGS LIMITED

By: /s/ Tang Chun Wai Nelson

Name: Tang Chun Wai Nelson

Title: Director

NAN FUNG LIFE SCIENCES HOLDINGS LIMITED

By: /s/ Sun Xintong

Name: Sun Xintong
Title: Director

NFLS PLATFORM HOLDINGS LIMITED

By: /s/ Sun Xintong

Name: Sun Xintong Title: Director

NFLS BETA LIMITED

By: /s/ Sun Xintong

Name: Sun Xintong
Title: Director

PIVOTAL LIFE SCIENCES HOLDINGS LIMITED

By: /s/ Sun Xintong

Name: Sun Xintong
Title: Director

PIVOTAL PARTNERS LTD

By: /s/ Sun Xintong

Name: Sun Xintong Title: Director

PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD

By: /s/ Robert Hopfner

Name: Robert Hopfner Title: Authorized Signatory

PIVOTAL BIOVENTURE PARTNERS FUND I G.P., L.P.

By: PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD

Its General Partner,

By: /s/ Robert Hopfner

Name: Robert Hopfner Title: Authorized Signatory

PIVOTAL BIOVENTURE PARTNERS FUND I, L.P.

By: PIVOTAL BIOVENTURE PARTNERS FUND I G.P., L.P.

Its General Partner,

By: PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD

Its General Partner,

By: /s/ Robert Hopfner

Name: Robert Hopfner
Title: Authorized Signatory

AGREEMENT

The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934.

Date: December 9, 2024

NAN FUNG GROUP HOLDINGS LIMITED

By: /s/ Tang Chun Wai Nelson

Name: Tang Chun Wai Nelson

Title: Director

NF INVESTMENT HOLDINGS LIMITED

By: /s/ Tang Chun Wai Nelson

Name: Tang Chun Wai Nelson

Title: Director

NAN FUNG LIFE SCIENCES HOLDINGS LIMITED

By: /s/ Sun Xintong

Name: Sun Xintong Title: Director

NFLS PLATFORM HOLDINGS LIMITED

By: /s/ Sun Xintong

Name: Sun Xintong Title: Director

NFLS BETA LIMITED

By: /s/ Sun Xintong

Name: Sun Xintong
Title: Director

PIVOTAL LIFE SCIENCES HOLDINGS LIMITED

By: /s/ Sun Xintong

Name: Sun Xintong Title: Director

PIVOTAL PARTNERS LTD

By: /s/ Sun Xintong

Name: Sun Xintong
Title: Director

PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD

By: /s/ Robert Hopfner

Name: Robert Hopfner Title: Director

PIVOTAL BIOVENTURE PARTNERS FUND I G.P., L.P.

By: PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD

Its General Partner,

By: /s/ Robert Hopfner

Name: Robert Hopfner Title: Authorized Signatory

PIVOTAL BIOVENTURE PARTNERS FUND I, L.P.

By: PIVOTAL BIOVENTURE PARTNERS FUND I G.P., L.P.

Its General Partner,

By: PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD

Its General Partner,

By: /s/ Robert Hopfner

Name: Robert Hopfner Title: Authorized Signatory